Table 1.
Clinical characteristics of the patients at the baseline.
| Before matching |
After matching |
|||||
|---|---|---|---|---|---|---|
| IGlar biosimilar | IGlar U300 | p | IGlar biosimilar | IGlar U300 | ||
| (n = 45) | (n = 149) | (n = 34) | (n = 102) | p | ||
| Male subjects (%) | 67 | 62 | .55 | 62 | 63 | .92 |
| Age (years) | 61 ± 12 | 67 ± 12 | <.01 | 65 ± 11 | 65 ± 12 | .87 |
| Duration of diabetes (years) | 12 ± 9 | 16 ± 11 | .03 | 14 ± 8 | 15 ± 10 | .99 |
| Body mass index (kg/m2) | 25.8 ± 5.6 | 25.4 ± 4.2 | .92 | 25.2 ± 5.3 | 25.9 ± 4.2 | .42 |
| Body weight (kg) | 69.1 ± 17.1 | 66.0 ± 13.7 | .44 | 65.9 ± 15.5 | 67.9 ± 13.7 | .29 |
| Dose of basal insulin (unit/day) | 10.6 ± 5.8 | 13.7 ± 7.6 | .01 | 11.6 ± 6.2 | 12.0 ± 6.3 | .67 |
| Dose of bolus insulin (unit/day) | 7.1 ± 8.6 | 10.0 ± 11.1 | .16 | 8.6 ± 9.2 | 8.7 ± 10.0 | .95 |
| Dose of total insulin (unit/day) | 17.7 ± 11.9 | 23.7 ± 14.6 | .01 | 20.2 ± 12.4 | 20.7 ± 13.4 | .96 |
| HbA1c (%) | 7.8 ± 1.1 | 8.1 ± 1.4 | .28 | 7.9 ± 1.1 | 7.9 ± 1.2 | .68 |
| Hypoglycemia within the past 6 months (%) | 9 | 16 | .21 | 12 | 13 | .88 |
| Concomitant anti-diabetic agents (%) | ||||||
| Sulfonylureas | 2 | 3 | .86 | 3 | 4 | .79 |
| Biguanides | 38 | 29 | .26 | 32 | 33 | .92 |
| Thiazolidinediones | 4 | 2 | .40 | 3 | 3 | .00 |
| α-glucosidase inhibitors | 11 | 9 | .55 | 12 | 8 | .50 |
| DPP-4 inhibitors | 56 | 41 | .08 | 47 | 46 | .92 |
| SGLT2 inhibitors | 16 | 10 | .16 | 12 | 10 | .75 |
| GLP-1 receptor agonists | 7 | 10 | .48 | 6 | 10 | .47 |
| Number of concomitant anti-diabetic agents | 1.4 ± 1.1 | 1.0 ± 0.8 | .05 | 1.2 ± 1.1 | 1.1 ± 0.8 | .98 |
Abbreviations. IGlar, insulin glargine; DPP-4, dipeptidyl peptidase-4; SGLT2, sodium glucose co-transporter 2; GLP-1, glucagon-like peptide-1.